REGN Regeneron Pharmaceuticals | $805.93 +0.3% | 8/17/2026 | | Boost Price Target | $641.00 ➝ $824.00 | Market Perform | 00.00% | View details for Leerink Partners rating of Regeneron Pharmaceuticals (NASDAQ:REGN) on 8/17/2026 |
FRNM Freenome | $13.00 +12.5% | 8/14/2026 | | Initiated Coverage | $18.00 | Outperform | 00.00% | View details for Leerink Partners rating of Freenome (NASDAQ:FRNM) on 8/14/2026 |
LGND Ligand Pharmaceuticals | $291.77 -1.0% | 8/14/2026 | | Initiated Coverage | $330.00 | Outperform | 00.00% | View details for Leerink Partners rating of Ligand Pharmaceuticals (NASDAQ:LGND) on 8/14/2026 |
SMMT Summit Therapeutics | $12.78 -4.3% | 8/12/2026 | | Upgrade | $12.00 ➝ $13.00 | Underperform ➝ Market Perform | 00.00% | View details for Leerink Partners rating of Summit Therapeutics (NASDAQ:SMMT) on 8/12/2026 |
CAH Cardinal Health | $235.68 +0.2% | 8/11/2026 | | Set Price Target | $292.00 | | 00.00% | View details for Leerink Partners rating of Cardinal Health (NYSE:CAH) on 8/11/2026 |
TENX Tenax Therapeutics | $1.71 -5.0% | 8/11/2026 | | Set Price Target | $4.00 | | 00.00% | View details for Leerink Partners rating of Tenax Therapeutics (NASDAQ:TENX) on 8/11/2026 |
IPHA Innate Pharma | $2.26 +3.7% | 8/11/2026 | | Upgrade | $4.00 | Market Perform ➝ Outperform | 00.00% | View details for Leerink Partners rating of Innate Pharma (NASDAQ:IPHA) on 8/11/2026 |
NTRA Natera | $314.18 +1.4% | 8/7/2026 | | Set Price Target | $330.00 | | 00.00% | View details for Leerink Partners rating of Natera (NASDAQ:NTRA) on 8/7/2026 |
AKBA Akebia Therapeutics | $0.86 -1.5% | 8/7/2026 | | Downgrade | $1.00 | Outperform ➝ Market Perform | 00.00% | View details for Leerink Partners rating of Akebia Therapeutics (NASDAQ:AKBA) on 8/7/2026 |
HALO Halozyme Therapeutics | $103.00 +4.4% | 8/7/2026 | | Upgrade | $83.00 ➝ $110.00 | Market Perform ➝ Outperform | 00.00% | View details for Leerink Partners rating of Halozyme Therapeutics (NASDAQ:HALO) on 8/7/2026 |
Get the Latest News and Ratings for Your Stocks Enter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter.
|
GDRX GoodRx | $3.72 -0.3% | 8/6/2026 | | Set Price Target | $5.00 | | 00.00% | View details for Leerink Partners rating of GoodRx (NASDAQ:GDRX) on 8/6/2026 |
EXEL Exelixis | $52.32 +2.1% | 8/6/2026 | | Downgrade | $52.00 | Outperform ➝ Market Perform | 00.00% | View details for Leerink Partners rating of Exelixis (NASDAQ:EXEL) on 8/6/2026 |
PODD Insulet | $139.70 -2.5% | 8/6/2026 | | Downgrade | $247.00 ➝ $145.00 | Outperform ➝ Market Perform | 00.00% | View details for Leerink Partners rating of Insulet (NASDAQ:PODD) on 8/6/2026 |
REPL Replimune Group | $14.63 -2.3% | 8/4/2026 | | Upgrade | $11.00 ➝ $17.00 | Market Perform ➝ Outperform | 00.00% | View details for Leerink Partners rating of Replimune Group (NASDAQ:REPL) on 8/4/2026 |
KROS Keros Therapeutics | $10.48 +3.8% | 8/4/2026 | | Lower Price Target | $30.00 ➝ $23.00 | Outperform | 00.00% | View details for Leerink Partners rating of Keros Therapeutics (NASDAQ:KROS) on 8/4/2026 |
LNTH Lantheus | $100.91 0.0% | 8/3/2026 | | Set Price Target | $102.50 | | 00.00% | View details for Leerink Partners rating of Lantheus (NASDAQ:LNTH) on 8/3/2026 |
INCY Incyte | $123.50 +2.8% | 8/3/2026 | | Boost Price Target | $131.00 ➝ $155.00 | Outperform | 00.00% | View details for Leerink Partners rating of Incyte (NASDAQ:INCY) on 8/3/2026 |
LNTH Lantheus | $100.91 0.0% | 8/3/2026 | | Downgrade | | Strong-Buy ➝ Hold | 00.00% | View details for Leerink Partners rating of Lantheus (NASDAQ:LNTH) on 8/3/2026 |
BSX Boston Scientific | $51.46 -0.7% | 7/30/2026 | | Set Price Target | $60.00 | | 00.00% | View details for Leerink Partners rating of Boston Scientific (NYSE:BSX) on 7/30/2026 |
HUM Humana | $383.18 -1.5% | 7/30/2026 | | Upgrade | $513.00 | Market Perform ➝ Outperform | 00.00% | View details for Leerink Partners rating of Humana (NYSE:HUM) on 7/30/2026 |
GOSS Gossamer Bio | $0.14 -9.2% | 7/28/2026 | | Upgrade | $1.00 | Market Perform ➝ Outperform | 00.00% | View details for Leerink Partners rating of Gossamer Bio (NASDAQ:GOSS) on 7/28/2026 |
EW Edwards Lifesciences | $90.84 -0.8% | 7/24/2026 | | Upgrade | $87.00 ➝ $101.00 | Market Perform ➝ Outperform | 00.00% | View details for Leerink Partners rating of Edwards Lifesciences (NYSE:EW) on 7/24/2026 |
MEDP Medpace | $597.12 +3.2% | 7/23/2026 | | Set Price Target | $620.00 | | 00.00% | View details for Leerink Partners rating of Medpace (NASDAQ:MEDP) on 7/23/2026 |
PGNY Progyny | $25.33 -3.6% | 7/22/2026 | | Set Price Target | $38.00 | | 00.00% | View details for Leerink Partners rating of Progyny (NASDAQ:PGNY) on 7/22/2026 |
GILD Gilead Sciences | $138.92 +0.4% | 7/21/2026 | | Downgrade | $146.00 ➝ $127.00 | Outperform ➝ Market Perform | 00.00% | View details for Leerink Partners rating of Gilead Sciences (NASDAQ:GILD) on 7/21/2026 |
STTK Shattuck Labs | $7.39 -0.4% | 7/20/2026 | | Initiated Coverage | $16.00 | Outperform | 00.00% | View details for Leerink Partners rating of Shattuck Labs (NASDAQ:STTK) on 7/20/2026 |
ELV Elevance Health | $390.69 -2.4% | 7/17/2026 | | Boost Price Target | $364.00 ➝ $395.00 | Market Perform | 00.00% | View details for Leerink Partners rating of Elevance Health (NYSE:ELV) on 7/17/2026 |
ILMN Illumina | $193.13 +1.2% | 7/17/2026 | | Boost Price Target | $175.00 ➝ $210.00 | Outperform | 00.00% | View details for Leerink Partners rating of Illumina (NASDAQ:ILMN) on 7/17/2026 |
TXG 10x Genomics | $57.99 +3.4% | 7/17/2026 | | Boost Price Target | $23.00 ➝ $40.00 | Market Perform | 00.00% | View details for Leerink Partners rating of 10x Genomics (NASDAQ:TXG) on 7/17/2026 |
ISRG Intuitive Surgical | $390.33 -1.1% | 7/17/2026 | | Lower Price Target | $573.00 ➝ $454.00 | Outperform | 00.00% | View details for Leerink Partners rating of Intuitive Surgical (NASDAQ:ISRG) on 7/17/2026 |
TWST Twist Bioscience | $124.41 +4.9% | 7/16/2026 | | Set Price Target | $110.00 | | 00.00% | View details for Leerink Partners rating of Twist Bioscience (NASDAQ:TWST) on 7/16/2026 |
KARD Kardigan | $20.55 +1.7% | 7/13/2026 | | Initiated Coverage | $37.00 | Outperform | 00.00% | View details for Leerink Partners rating of Kardigan (NASDAQ:KARD) on 7/13/2026 |
NGEN NervGen Pharma | $1.68 -3.2% | 7/13/2026 | | Initiated Coverage | $10.00 | Outperform | 00.00% | View details for Leerink Partners rating of NervGen Pharma (NASDAQ:NGEN) on 7/13/2026 |
WHWK Whitehawk Therapeutics | $4.64 +4.0% | 7/13/2026 | | Initiated Coverage | $9.00 | Outperform | 00.00% | View details for Leerink Partners rating of Whitehawk Therapeutics (NASDAQ:WHWK) on 7/13/2026 |
BRKR Bruker | $57.67 -0.1% | 7/7/2026 | | Boost Price Target | $60.00 ➝ $70.00 | Outperform | 00.00% | View details for Leerink Partners rating of Bruker (NASDAQ:BRKR) on 7/7/2026 |
AVTX Avalo Therapeutics | $19.95 +1.8% | 7/6/2026 | | Initiated Coverage | $38.00 | Outperform | 00.00% | View details for Leerink Partners rating of Avalo Therapeutics (NASDAQ:AVTX) on 7/6/2026 |
PBLS Parabilis Medicines | $37.22 +0.4% | 7/6/2026 | | Initiated Coverage | $40.00 | Outperform | 00.00% | View details for Leerink Partners rating of Parabilis Medicines (NASDAQ:PBLS) on 7/6/2026 |
PYXS Pyxis Oncology | $3.02 +0.3% | 7/2/2026 | | Lower Price Target | $9.00 ➝ $7.00 | Outperform | 00.00% | View details for Leerink Partners rating of Pyxis Oncology (NASDAQ:PYXS) on 7/2/2026 |
MLTX MoonLake Immunotherapeutics | $16.35 -0.7% | 7/1/2026 | | Boost Price Target | $24.00 ➝ $29.00 | Outperform | 00.00% | View details for Leerink Partners rating of MoonLake Immunotherapeutics (NASDAQ:MLTX) on 7/1/2026 |
ABVX Abivax | $120.73 +1.5% | 6/30/2026 | | Boost Price Target | $140.00 ➝ $148.00 | Outperform | 00.00% | View details for Leerink Partners rating of Abivax (NASDAQ:ABVX) on 6/30/2026 |
Trump's New Dollar (Ad) Porter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. dollar reset - and most Americans don't know it's happening.
The last time America underwent a monetary shift like this, under Nixon in the 1970s, it minted an average of 1,300 new millionaires a day for over half a century. Stansberry has released a new documentary naming the assets he believes are positioned to surge as a result. Watch the free briefing and see the three steps to prepare today |
TECH Bio-Techne | $72.39 0.0% | 6/25/2026 | | Set Price Target | $73.00 | | 00.00% | View details for Leerink Partners rating of Bio-Techne (NASDAQ:TECH) on 6/25/2026 |
LLY Eli Lilly and Company | $1,184.44 +0.4% | 6/25/2026 | | Boost Price Target | $1,119.00 ➝ $1,232.00 | Outperform | 00.00% | View details for Leerink Partners rating of Eli Lilly and Company (NYSE:LLY) on 6/25/2026 |
IONS Ionis Pharmaceuticals | $58.63 +2.4% | 6/25/2026 | | Boost Price Target | $122.00 ➝ $129.00 | Outperform | 00.00% | View details for Leerink Partners rating of Ionis Pharmaceuticals (NASDAQ:IONS) on 6/25/2026 |
SPRY ARS Pharmaceuticals | $6.24 +10.4% | 6/25/2026 | | Lower Price Target | $25.00 ➝ $24.00 | Outperform | 00.00% | View details for Leerink Partners rating of ARS Pharmaceuticals (NASDAQ:SPRY) on 6/25/2026 |
TECH Bio-Techne | $72.39 0.0% | 6/25/2026 | | Downgrade | | Strong-Buy ➝ Hold | 00.00% | View details for Leerink Partners rating of Bio-Techne (NASDAQ:TECH) on 6/25/2026 |
QNCX Quince Therapeutics | $34.12 +0.2% | 6/24/2026 | | Initiated Coverage | $80.00 | Outperform | 00.00% | View details for Leerink Partners rating of Quince Therapeutics (NASDAQ:QNCX) on 6/24/2026 |
RAPP Rapport Therapeutics | $48.42 +2.1% | 6/24/2026 | | Initiated Coverage | $52.00 | Outperform | 00.00% | View details for Leerink Partners rating of Rapport Therapeutics (NASDAQ:RAPP) on 6/24/2026 |
RGNX REGENXBIO | $11.33 +5.2% | 6/22/2026 | | Boost Price Target | $17.00 ➝ $18.00 | Outperform | 00.00% | View details for Leerink Partners rating of REGENXBIO (NASDAQ:RGNX) on 6/22/2026 |
DFTX Definium Therapeutics | $45.26 +6.2% | 6/22/2026 | | Set Price Target | $30.00 ➝ $52.00 | Outperform | 00.00% | View details for Leerink Partners rating of Definium Therapeutics (NASDAQ:DFTX) on 6/22/2026 |
ALT Altimmune | $3.00 +2.0% | 6/22/2026 | | Initiated Coverage | $10.00 | Outperform | 00.00% | View details for Leerink Partners rating of Altimmune (NASDAQ:ALT) on 6/22/2026 |
QURE uniQure | $47.97 -1.3% | 6/18/2026 | | Boost Price Target | $36.00 ➝ $70.00 | Outperform | 00.00% | View details for Leerink Partners rating of uniQure (NASDAQ:QURE) on 6/18/2026 |
ARWR Arrowhead Pharmaceuticals | $88.70 +2.4% | 6/17/2026 | | Boost Price Target | $61.00 ➝ $72.00 | Market Perform | 00.00% | View details for Leerink Partners rating of Arrowhead Pharmaceuticals (NASDAQ:ARWR) on 6/17/2026 |
IONS Ionis Pharmaceuticals | $58.63 +2.4% | 6/17/2026 | | Boost Price Target | $114.00 ➝ $122.00 | Outperform | 00.00% | View details for Leerink Partners rating of Ionis Pharmaceuticals (NASDAQ:IONS) on 6/17/2026 |
UNH UnitedHealth Group | $395.02 -1.7% | 6/17/2026 | | Boost Price Target | $400.00 ➝ $462.00 | Outperform | 00.00% | View details for Leerink Partners rating of UnitedHealth Group (NYSE:UNH) on 6/17/2026 |
EWTX Edgewise Therapeutics | $44.04 -0.3% | 6/16/2026 | | Set Price Target | $52.00 | | 00.00% | View details for Leerink Partners rating of Edgewise Therapeutics (NASDAQ:EWTX) on 6/16/2026 |
SABS SAB Biotherapeutics | $3.77 +1.9% | 6/15/2026 | | Boost Price Target | $7.00 ➝ $12.00 | Outperform | 00.00% | View details for Leerink Partners rating of SAB Biotherapeutics (NASDAQ:SABS) on 6/15/2026 |
PRCT PROCEPT BioRobotics | $21.09 -2.6% | 6/11/2026 | | Downgrade | $31.00 ➝ $29.00 | Outperform ➝ Market Perform | 00.00% | View details for Leerink Partners rating of PROCEPT BioRobotics (NASDAQ:PRCT) on 6/11/2026 |
TNGX Tango Therapeutics | $25.29 -1.2% | 6/8/2026 | | Boost Price Target | $55.00 ➝ $69.00 | Outperform | 00.00% | View details for Leerink Partners rating of Tango Therapeutics (NASDAQ:TNGX) on 6/8/2026 |
SYK Stryker | $331.75 -2.2% | 6/5/2026 | | Lower Price Target | $410.00 ➝ $407.00 | Outperform | 00.00% | View details for Leerink Partners rating of Stryker (NYSE:SYK) on 6/5/2026 |
NBTX Nanobiotix | $42.05 +9.8% | 6/4/2026 | | Boost Price Target | $37.00 ➝ $46.00 | Outperform | 00.00% | View details for Leerink Partners rating of Nanobiotix (NASDAQ:NBTX) on 6/4/2026 |
ABSI Absci | $9.24 +0.7% | 6/4/2026 | | Initiated Coverage | $12.00 | Outperform | 00.00% | View details for Leerink Partners rating of Absci (NASDAQ:ABSI) on 6/4/2026 |
MDT Medtronic | $90.44 -0.9% | 6/4/2026 | | Lower Price Target | $117.00 ➝ $104.00 | Outperform | 00.00% | View details for Leerink Partners rating of Medtronic (NYSE:MDT) on 6/4/2026 |
NUVL Nuvalent | $123.96
| 6/3/2026 | | Set Price Target | $165.00 | | 00.00% | View details for Leerink Partners rating of Nuvalent (NASDAQ:NUVL) on 6/3/2026 |
VIR Vir Biotechnology | $9.39 +1.6% | 6/3/2026 | | Boost Price Target | $20.00 ➝ $21.00 | Outperform | 00.00% | View details for Leerink Partners rating of Vir Biotechnology (NASDAQ:VIR) on 6/3/2026 |
CELC Celcuity | $92.44 +0.5% | 6/2/2026 | | Set Price Target | $155.00 | | 00.00% | View details for Leerink Partners rating of Celcuity (NASDAQ:CELC) on 6/2/2026 |
FULC Fulcrum Therapeutics | $3.84 +2.7% | 6/2/2026 | | Downgrade | $4.00 | Outperform ➝ Market Perform | 00.00% | View details for Leerink Partners rating of Fulcrum Therapeutics (NASDAQ:FULC) on 6/2/2026 |
XFOR X4 Pharmaceuticals | $4.30 +1.9% | 6/2/2026 | | Initiated Coverage | $12.00 | Outperform | 00.00% | View details for Leerink Partners rating of X4 Pharmaceuticals (NASDAQ:XFOR) on 6/2/2026 |
ICLR Icon | $169.45 +3.9% | 5/28/2026 | | Set Price Target | $145.00 | | 00.00% | View details for Leerink Partners rating of Icon (NASDAQ:ICLR) on 5/28/2026 |
BSX Boston Scientific | $51.46 -0.7% | 5/28/2026 | | Lower Price Target | $87.00 ➝ $74.00 | Outperform | 00.00% | View details for Leerink Partners rating of Boston Scientific (NYSE:BSX) on 5/28/2026 |
EQ Equillium | $2.48 +5.1% | 5/28/2026 | | Upgrade | $1.00 ➝ $6.00 | Market Perform ➝ Outperform | 00.00% | View details for Leerink Partners rating of Equillium (NASDAQ:EQ) on 5/28/2026 |
LLY Eli Lilly and Company | $1,184.44 +0.4% | 5/26/2026 | | Set Price Target | $1,119.00 | | 00.00% | View details for Leerink Partners rating of Eli Lilly and Company (NYSE:LLY) on 5/26/2026 |
SPTX Seaport Therapeutics | $24.40 +0.7% | 5/26/2026 | | Initiated Coverage | $35.00 | Outperform | 00.00% | View details for Leerink Partners rating of Seaport Therapeutics (NASDAQ:SPTX) on 5/26/2026 |
TWST Twist Bioscience | $124.41 +4.9% | 5/22/2026 | | Set Price Target | $80.00 | | 00.00% | View details for Leerink Partners rating of Twist Bioscience (NASDAQ:TWST) on 5/22/2026 |
EHC Encompass Health | $121.94 -1.3% | 5/22/2026 | | Set Price Target | $152.00 | | 00.00% | View details for Leerink Partners rating of Encompass Health (NYSE:EHC) on 5/22/2026 |
ROIV Roivant Sciences | $36.24 +0.1% | 5/21/2026 | | Set Price Target | $42.00 | | 00.00% | View details for Leerink Partners rating of Roivant Sciences (NASDAQ:ROIV) on 5/21/2026 |
CGEN Compugen | $2.35 -2.5% | 5/21/2026 | | Lower Price Target | $13.00 ➝ $5.00 | Outperform | 00.00% | View details for Leerink Partners rating of Compugen (NASDAQ:CGEN) on 5/21/2026 |
IRD Opus Genetics | $3.65 +1.1% | 5/21/2026 | | Initiated Coverage | $10.00 | Outperform | 00.00% | View details for Leerink Partners rating of Opus Genetics (NASDAQ:IRD) on 5/21/2026 |
REGN Regeneron Pharmaceuticals | $805.93 +0.3% | 5/18/2026 | | Reiterated Rating | $792.00 ➝ $641.00 | Outperform ➝ Market Perform | 00.00% | View details for Leerink Partners rating of Regeneron Pharmaceuticals (NASDAQ:REGN) on 5/18/2026 |
ONC BeOne Medicines | $362.51 +4.3% | 5/15/2026 | | Boost Price Target | $364.00 ➝ $367.00 | Outperform | 00.00% | View details for Leerink Partners rating of BeOne Medicines (NASDAQ:ONC) on 5/15/2026 |
ANAB AnaptysBio | $59.69 +2.1% | 5/15/2026 | | Set Price Target | $90.00 | | 00.00% | View details for Leerink Partners rating of AnaptysBio (NASDAQ:ANAB) on 5/15/2026 |
IMNM Immunome | $27.40 +0.7% | 5/15/2026 | | Lower Price Target | $37.00 ➝ $33.00 | Outperform | 00.00% | View details for Leerink Partners rating of Immunome (NASDAQ:IMNM) on 5/15/2026 |
STRO Sutro Biopharma | $22.28 +8.8% | 5/15/2026 | | Set Price Target | $38.00 ➝ $43.00 | Outperform | 00.00% | View details for Leerink Partners rating of Sutro Biopharma (NASDAQ:STRO) on 5/15/2026 |
RNA Avidity Biosciences | $12.96 +0.9% | 5/15/2026 | | Initiated Coverage | | Outperform | 00.00% | View details for Leerink Partners rating of Avidity Biosciences (NASDAQ:RNA) on 5/15/2026 |
DOCS Doximity | $24.60 -0.8% | 5/14/2026 | | Lower Price Target | $31.00 ➝ $25.00 | Outperform | 00.00% | View details for Leerink Partners rating of Doximity (NYSE:DOCS) on 5/14/2026 |
AIRS AirSculpt Technologies | $3.09 -9.9% | 5/14/2026 | | Set Price Target | $4.50 | | 00.00% | View details for Leerink Partners rating of AirSculpt Technologies (NASDAQ:AIRS) on 5/14/2026 |
ANTX Anthem | $5.73 -4.3% | 5/14/2026 | | Upgrade | $9.00 | Market Perform ➝ Outperform | 00.00% | View details for Leerink Partners rating of Anthem (NASDAQ:ANTX) on 5/14/2026 |
TNGX Tango Therapeutics | $25.29 -1.2% | 5/14/2026 | | Boost Price Target | $28.00 ➝ $55.00 | Outperform | 00.00% | View details for Leerink Partners rating of Tango Therapeutics (NASDAQ:TNGX) on 5/14/2026 |
JNJ Johnson & Johnson | $262.43 +0.8% | 5/13/2026 | | Upgrade | $265.00 | Market Perform ➝ Outperform | 00.00% | View details for Leerink Partners rating of Johnson & Johnson (NYSE:JNJ) on 5/13/2026 |
AURA Aura Biosciences | $7.68 -0.1% | 5/12/2026 | | Set Price Target | $17.00 | | 00.00% | View details for Leerink Partners rating of Aura Biosciences (NASDAQ:AURA) on 5/12/2026 |
ALMR Alamar Biosciences | $32.13 -3.1% | 5/12/2026 | | Initiated Coverage | $35.00 | Outperform | 00.00% | View details for Leerink Partners rating of Alamar Biosciences (NASDAQ:ALMR) on 5/12/2026 |
ALERT: Drop these 5 stocks before the market opens tomorrow! (Ad) The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings research points to the first half of 2026 as a particularly rough stretch for certain holdings.
Some of America's most popular stocks could take serious damage as a radical market shift plays out. Analysts at Weiss Ratings have identified five names you may want to remove from your portfolio before this unfolds.
If any of these are in your portfolio, now is the time to review your positions. See the 5 stocks to avoid |
KLRA Kailera Therapeutics | $18.51 +3.2% | 5/12/2026 | | Initiated Coverage | $36.00 | Outperform | 00.00% | View details for Leerink Partners rating of Kailera Therapeutics (NASDAQ:KLRA) on 5/12/2026 |
ENGN enGene | $1.70
| 5/8/2026 | | Downgrade | $2.00 | Outperform ➝ Market Perform | 00.00% | View details for Leerink Partners rating of enGene (NASDAQ:ENGN) on 5/8/2026 |
GILD Gilead Sciences | $138.92 +0.4% | 5/8/2026 | | Lower Price Target | $148.00 ➝ $146.00 | | 00.00% | View details for Leerink Partners rating of Gilead Sciences (NASDAQ:GILD) on 5/8/2026 |
PODD Insulet | $139.70 -2.5% | 5/7/2026 | | Lower Price Target | $360.00 ➝ $247.00 | | 00.00% | View details for Leerink Partners rating of Insulet (NASDAQ:PODD) on 5/7/2026 |
TWST Twist Bioscience | $124.41 +4.9% | 5/5/2026 | | Upgrade | $70.00 | Market Perform ➝ Outperform | 00.00% | View details for Leerink Partners rating of Twist Bioscience (NASDAQ:TWST) on 5/5/2026 |
ICLR Icon | $169.45 +3.9% | 5/4/2026 | | Set Price Target | $125.00 | | 00.00% | View details for Leerink Partners rating of Icon (NASDAQ:ICLR) on 5/4/2026 |
ORKA Oruka Therapeutics | $112.66 +1.5% | 4/30/2026 | | Set Price Target | $120.00 | | 00.00% | View details for Leerink Partners rating of Oruka Therapeutics (NASDAQ:ORKA) on 4/30/2026 |
ALGN Align Technology | $171.16 -5.6% | 4/30/2026 | | Boost Price Target | $225.00 ➝ $230.00 | | 00.00% | View details for Leerink Partners rating of Align Technology (NASDAQ:ALGN) on 4/30/2026 |
HUM Humana | $383.18 -1.5% | 4/30/2026 | | Boost Price Target | $185.00 ➝ $255.00 | Market Perform | 00.00% | View details for Leerink Partners rating of Humana (NYSE:HUM) on 4/30/2026 |
NEO NeoGenomics | $16.16 +1.4% | 4/29/2026 | | Upgrade | $12.00 ➝ $25.00 | Market Perform ➝ Outperform | 00.00% | View details for Leerink Partners rating of NeoGenomics (NASDAQ:NEO) on 4/29/2026 |